AAPS PharmSciTech

, Volume 9, Issue 1, pp 169–173 | Cite as

Controlled Ocular Delivery of Acyclovir through Rate Controlling Ocular Insert of Eudragit: A Technical Note

  • Shagufta Khan
  • Asgar Ali
  • Dilesh Singhavi
  • Pramod Yeole
Brief/Technical Note

Key words

acyclovir aqueous humor eudragit ocular insert ophthalmic insert sodium alginate 


  1. 1.
    S. D. Desai, and J. Blanchard. Ocular drug formulation and delivery. In J. Swarbrick, and J. Boylar (eds.), Encyclopedia of Pharmaceutical Technology, Vol. 3, Marcel Dekker, New York, 1994, pp. 43–76.Google Scholar
  2. 2.
    R. D. Schoenwald. Ocular drug delivery, pharmacokinetic considerations. Clin. Pharmacokinet. 18:255–269 (1998).CrossRefGoogle Scholar
  3. 3.
    V. H. L. Lee. Precorneal, corneal and postcorneal factors. Drugs Pharm. Sci. 58:59–81 (1993).Google Scholar
  4. 4.
    M. A. Attis, M. A. Kassem, and S. Safewat. In vivo performance of [3H] dexamethasone ophthalmic film delivery systems in the rabbit eye. Int. J. Pharm. 47:21–30 (1988).CrossRefGoogle Scholar
  5. 5.
    S. Barath, and S. R. Hiremath. Ocular delivery system of perfloxacin mesylate. Pharmazie 54:33–38 (1999).Google Scholar
  6. 6.
    L. R. Humo, H. K. Lee, L. Benedetti, Y. D. Sanagiri, E. M. Topp, and V. J. Stella. Ocular sustained delivery of prednisolone using hyaluronic acid benzyl ester films. Int. J. Pham. 111:293–298 (1994).Google Scholar
  7. 7.
    F. Gurtler, V. Kaltsatos, B. Boisrame, and R. Gurny. Long-acting soluble bioadhesive ophthalmic drug insert (BODI) containing gentamycin for veternary use : optimization and clinical investigation. J. Control. Release 33:231–236 (1995).CrossRefGoogle Scholar
  8. 8.
    S. Kawakami, K. Nishida, T. Mukai, K. Yamamura, J. Nakamura, T. Sakaeda, M. Nakashima, and H. Sasaki. Controlled release and ocular absorption of tilisolol utilizing ophthalmic insert-incorporated lipophilic prodrugs. J. Control. Release 70:255–263 (2001).CrossRefGoogle Scholar
  9. 9.
    G. Di Colo, and Y. Zambito. A study of release mechanisms of different ophthalmic drugs from erodible ocular inserts based on poly(ethylene oxide). Eur. J. Pharm. Biopharm. 54:193–199 (2002).CrossRefGoogle Scholar
  10. 10.
    Sean C Sweetness(Ed). Martindale: The Complete Drug Reference.33rd ed, Vol.I, The Pharmaceutical Press, London; 2002:605–648.Google Scholar
  11. 11.
    C. Giannavola, C. Bucolo, A. Maltese, D. Paolino, M. A. Vandelli, G. Puglisi, V. H. Lee, and M. Fresta. Influence of preparation conditions on acyclovir-loaded poly-d,l-lactic acid nanospheres and effect of PEG coating on ocular drug bioavailability. Pharm Res. 20:584–590 (2003).CrossRefGoogle Scholar
  12. 12.
    M. Fresta, G. Fontana, C. Bucolo, G. Cavallaro, G. Giammona, and G. Puglisi. Ocular tolerability and in vivo bioavailability of poly(ethylene glycol) (PEG)-coated polyethyl-2-cyanoacrylate nanosphere-encapsulated acyclovir. J. Pharm. Sci. 90:288–297 (2001).CrossRefGoogle Scholar
  13. 13.
    A. Ali, S. N. Sharma. Fabrication of a through-flow apparatus for in-vitro determination of drugs from ophthalmic preparations. Indian Drugs 29:157–160 (1992).Google Scholar
  14. 14.
    A. Ali, S. N. Sharma. Cromolyn sodium in the treatment of allergic conjunctivitis caused by congress grass. Ind. J. Hosp. Pharm 28:163–169 (1991).Google Scholar
  15. 15.
    N. Castela, N. Vermerie, F. Chast, H. Saubegeon-Martre, J. Denis, V. Godard, P. Goldschmidt, and Y. Pouliquen. Gancyclovir ophthalmic gel in herpes simplex virus rabbit keratitis: Intraocular penetration and efficacy. J. Ocul. Pharmacol. 10:439–451 (1994).Google Scholar
  16. 16.
    I. Genta, B. Conti, P. Perugini, F. Pavanetto, A. Spadaro, and G. Puglisi. Bioahesive microsheres for ophthalmic administration of acyclovir. J. Pharm. Pharmacol. 49:737–742 (1997).Google Scholar
  17. 17.
    V. Rao, and S. Shyale. Preparation and evaluation of ocular inserts containing norfloxacin. Turk. J. Med. Sci. 34:239–246 (2004).Google Scholar
  18. 18.
    A. J. Wagstaff, D. Faulds, K. L. Goa. Acyclovir: a reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic efficacy. Drug 47:153–205 (1994).CrossRefGoogle Scholar

Copyright information

© American Association of Pharmaceutical Scientists 2007

Authors and Affiliations

  • Shagufta Khan
    • 1
  • Asgar Ali
    • 2
  • Dilesh Singhavi
    • 1
  • Pramod Yeole
    • 1
  1. 1.Institute of Pharmaceutical Education and Research (IPER)WardhaIndia
  2. 2.Faculty of Pharmacy, Jamia HamdardHamdard UniversityNew Delhi-62India

Personalised recommendations